+ was made in a 42-year-old woman, 12 months after the treatment of uterine adenocarcinoma by carboplatinum, anthracyclines, etoposide and radiotherapy. Molecular cytogenetic studies revealed a karyotype with multiple chromosome changes, including the t(4;11)(q21;q23) and a 17p-chromosome, with MLL disruption and 17p13/p53 gene deletion in 86% of the cells. A p53 exon 6 mutation was documented, resulting in p53 protein stabilization, with 20% of the cells reacting with the 1801 anti-p53 monoclonal antibody. Dual-color FISH using MLL and p53 probes was performed on peripheral blood smears, providing direct evidence of the involvement of the blast cells and of the granulocytic lineage. Only a partial, shortlasting response was obtained by induction treatment, confirming that a poor prognosis is associated with therapy-related ALL with the 4;11 translocation.
Introduction
The treatment of a primary neoplasm by alkylating agents, radiation therapy, and topoisomerase-II inhibitors (topo-II) is complicated by the onset of acute leukemia, occurring in 5-10% of cases after 6 months to 10 years. These leukemias, usually referred to as therapy-related acute leukemia, are almost invariably of myeloid lineage and display peculiar biologic features identifying two distinct clinical entities. The former develops after the administration of alkylating agents ± radiotherapy. It is characterized by a relatively prolonged latency period, by −5/5q− and/or −7/7q− chromosomes, by the association with myelodysplasia and by a uniformly severe clinical outcome. The latter, deriving from the rearrangement of the MLL gene at the 11q23 band or, less frequently, of the core-binding factor genes AML1 and MYH11 at 21q22 and 16q22, respectively, is associated with previous administration of cis-platinum, epipodophyllotoxins, anthracyclines. A relatively short latency period of 6 months to 3 years, the absence of an MDS phase and a more favorable clinical outcome have been reported in this form of leukemia. 1 Occasionally, cases of acute lymphoblastic leukemia (ALL) have been reported after the use of topo-II inhibitors [2] [3] [4] [5] but the clinicobiologic features of these leukemias are poorly defined. Hematologic and molecular cytogenetic features in one such case are presented in this report, in an attempt to outline better the cytogenetic profile of this rare form of leukemia and to analyze the cell lineages that may be involved by the leukemic process. 
Case history
A 42-year-old woman was admitted to our Institution in 1995, 12 months after treatment of uterine adenocarcinoma by local surgery followed by multiagent chemotherapy (eight courses of carboplatinum, epirubicin and etoposide) and subsequent pelvic irradiation (total dose 56 Gy).
On admission the patient presented anemia (Hb 9 g/dl), thrombocytopenia (Plt 45 × 10 9 l), and hyperleukocytosis (WBC 400 000 × 10 9 l, with 96% blast cells). A monotonous infiltrate of small and medium-sized blast cells, with high nucleo-cytoplasmic ratio was noted at bone marrow (BM) aspiration. Cytochemical findings were unremarkable (negativity for the periodic acid-Schiff stain and peroxidase); cytofluorimetric analysis was performed as previously reported, 6 − , myeloid markers (CD13 and CD33) negative, T cell markers (CD7, CD2, CD3) negative. A diagnosis of ALL-L2 was made and induction treatment was started using vincristine, daunorubicin, prednisone, asparaginase and cytarabine. Only a partial, short-lasting response was obtained and the patient died 4 months later with active leukemia and cerebral hemorrage.
Cytogenetic and molecular genetic studies

Cytogenetics
Bone marrow cells were cultured for 24 and 48 h in RPMI medium with the addition of 10% fetal calf serum. The cytogenetic procedure included mitotic block by colcemid, hypotonic shock in 0.075 m KCl solution and fixation in 3:1 methanol/acetic acid solution. Karyotype aberrations were described according to the ISCN. 7 
FISH
Specimens:
Slides for FISH studies were prepared from the fixed cell suspension that was used for cytogenetic diagnosis; in addition, unstained PB smears prepared at diagnosis were used for the analysis of the correlation of morphology and hybridization pattern.
Probes:
The 13HH4 YAC probe encompassing the region at 11q23, where MLL gene breakpoints are located, was pre- These probes were tested on five normal control samples, yielding scorable signals in over 80% of interphase nuclei. Two hundred cells with well delineated signals were counted: a normal hybridization pattern, consisting of two fluorescent spots was seen in Ͼ95% cells using the MLL probe and in Ͼ92% cells using the 17p13/p53 probe.
Hybridization:
The MLL YAC probe was biotinylated and the p53 cosmid probe was digoxigenated according to standard methods; simultaneous hybridization of these probes was performed and dual-color visualization of hybridization signals was obtained by amplification using FITC-avidin (MLL probe) and Texas red-conjugated anti-digoxigenin-monoclonal antibodies (p53 probe), as previously described. 6 Hybridization conditions, methods for amplification and signal have been previously described. 6, 8, 9 p53 analysis DNA was isolated from PB cells at diagnosis and extracted as described previously. 10 Briefly, 10 mg DNA were digested with BamHI, EcoRI and HindIII restriction enzymes, separated on agarose gel, Southern blotted and hybridized with a 1.8 kb p53 cDNA fragment encompassing 5Ј and 3Ј untranslated sequences. The presence of small p53 gene mutations was studied by polymerase chain reaction/single strand conformation polymorphism (PCR-SSCP). The exons 5-9, known to be involved in the vast majority of mutations reported in hematologic neoplasms, were amplified and their electrophoretic mobility was analyzed. Amplified fragments in low melting agarose gel were subjected to direct nucleotide sequence by the dideoxynucleotide method using the Sequenase version 2.0 kit (United States Biochemical Corp, Cleveland, OH, USA).
p53 expression was determined by flow cytometry (FACScan 488 nm laser Argon equipped; Becton Dickinson, San Jose, CA, USA) on peripheral blood (PB) cells taken at diagnosis, fixed in paraformaldehyde-lysine-periodate solution following incubation with the 1801 monoclonal antibody (MoAb). This MoAb was shown to detect the mutant and wild-type protein, recognizing the N-terminal epitope 11 and yielded a Ͻ5% positivity in normal PB and BM cells in our laboratory while efficiently detecting p53 proteins 'stabilized' by mutations. The analysis was performed with a Lysis II software program; reactivity of cells with low side scatter property (lymphocyte and blast gate) and cells with high side scatter property (neutrophil gate) was assessed.
MLL-AF4 RT-PCR amplification and sequencing
The detailed description of the MLL-AF4 reverse transcription amplification has been reported elsewhere. 12 The sequences of primers used were as follows: Ex 5, 5Ј-GAG GAT CCT GCC CCA AAG AAA AG-3Ј sense; Ex 6, 5Ј-CGC CCA AGT ATC CCT GTA AAA C-3Ј sense; AF4.1, 5Ј-TGA GCT GAA GCT GGT CTT CGA GC-3Ј antisense. Purified MLL/AF4 PCR products were then sequenced directly by the dideoxynucleotide chain termination method with a modified T7 DNA polymerase (Sequenase 2.0) using as sequencing primer either one of the two oligomers used for PCR amplification.
Results
The karyotype was described as follows: 46,XX, t(3;6) (p21;q21), del(3)(p24), t(4;11)(q21;q23), del(6)(q15), i(7)(q10), add(9)(p22), del(17)(p11) [cp13]/46,XX [7] . Sequencing of the junction fragments of the 4;11 translocation showed that a 286-bp product resulted from fusion of MLL exon 6 to AF4 site A (ie nucleotide number 1414 of AF4) (data not shown).
Dual-color FISH on cytogenetic preparations revealed three MLL signals (one deriving from the normal allele, two from the split allele that was involved in the translocation) and one p53 signal in 86% of the cells. The remaining cells had three MLL/no p53 signals (5%), two MLL/one p53 signals (5%) and two MLL/two p53 signals (4%).
A total of 30 neutrophils and 100 mononuclear cells with well delineated signals were analyzed on peripheral blood smears after dual-color hybridization with the MLL and the 17p13/p53 probes (see Figure 1) No evidence of p53 rearrangement with the cDNA probe was obtained by Southern blotting and no altered electrophoretic mobility of exons 5-9 was detected by PCR/SSCP analysis. Because SSCP may yield false negative results, direct sequencing of exons 5-8 was performed, showing a transversion from C to A at codon 223, exon 6 (Figure 2) , changing a CCT to CAT and causing a missense mutation from Pro to His. Positivity for the anti-p53 monoclonal antibody was found in 20% and 18% of the PB cells, in the blast gate and the neutrophil gate, respectively.
Discussion
The 4;11 translocation and the corresponding MLL gene involvement occur in the majority of infant leukemia and in 5% of de novo adult ALL. 12 Secondary ALL is relatively rare and data from 11 such cases with t(4;11) have been reported in the literature, [2] [3] [4] showing an onset 0.75-22 years (median 2) after cytotoxic treatment and a uniformly short survival (1-13 months, median 3.5). Similar findings were described by Secker-Walker et al 5 who reported nine additional cases drawn from a large multicentre study.
This case of t-ALL displayed the typical features of t(4;11) leukemia in that it showed L2 morphology a pro-B phenotype with CD15 expression, CD10, TdT negativity, a profile of additional chromosome changes frequently found in this leukemia (ie gain of 7q, losses of 7p and 17p) 13, 14 and a severe outcome. Unlike the majority of previously reported t-ALL, 11 the breakpoint in the MLL gene in this patient involved the centromeric portion (exon 6) of the breakpoint cluster region.
The potential relevance of the association of t(4;11)/MLL rearrangement and 17p−/p53 deletion deserves further comment. These molecular cytogenetic defects were detected in all abnormal metaphases and in the majority of mononuclear cells and neutrophils, proving that both lesions occurred early in the transformation process. 15 The 17p deletion was shown by FISH to involve the p53 gene, which showed an exon 6 missense mutation in the remaining allele. As expected, p53 stabilization occurred, since reactivity with the anti-wild-type p53 monoclonal antibody was detected in approximately 20% of the cells, both in the blast gate and in the cells with high side scatter, corresponding to cells of the granulocytic lineage. p53 gene mutations were found infrequently in ALL at diagnosis, although a preferential association of p53 gene mutations with MLL-rearranged leukemias was previously reported by Lanza et al 16 and by Cimino et al.
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Figure 2
Analysis by PCR direct sequencing of p53 exon VI. DNA from a control subject (N) and the patient (M) was amplified as previously described. 10 The mutation changed codon 223 from CCT (Pro) to CAT (His). A different missense mutation at this codon has been previously described in a prostate and a thyroid cell line changing CCT to CTT (Leu), as reported in the EMBL p53 mutation data base.
We provided direct evidence using FISH methodology, that multilineage involvement occurred in this leukemia. The simultaneous analysis of hybridization pattern and cell morphology proved to be an efficient method for the study of lineage involvement in hemopoietic neoplasms 8, 9, 17 and unequivocally showed that the target stem cell for leukemogenesis in this case of t(4;11) leukemia retained the capability to differentiate in vivo along the lymphoid and granulocytic pathways.
The hypothesis that some of the MLL-rearranged leukemias, including ALL with t(4;11), derived from the transformation of a pluripotent stem cell has been supported in the past by several lines of indirect evidence, including in vitro studies documenting differentiation of lymphoid blasts into monocytic cells, 18 the occurrence of lineage switch at relapse 19 and bidirectional differentiation into leukemia and B-lymphoma. 20 The possibility should be considered that heterogeneity of differentiation patterns of leukemic cells may occur within this subset of leukemia and it is noteworthy that different patterns of lineage involvement in Philadelphia chromosome-positive ALL were shown have a correlation with prognosis. 8, 21 The chance to test this hypothesis using a simple and direct method, may facilitate the assessment of the correlation of lineage involvement and prognosis in t(4;11) ALL.
